摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

15-acetyl-5,6,12,13-tetrahydrocycloocta[1,2-f:5,6-f']bis[1,3]benzodioxol-5,12-imine | 167491-69-2

中文名称
——
中文别名
——
英文名称
15-acetyl-5,6,12,13-tetrahydrocycloocta[1,2-f:5,6-f']bis[1,3]benzodioxol-5,12-imine
英文别名
Californine-M (nor-) AC;1-(5,7,16,18-tetraoxa-23-azahexacyclo[10.10.1.02,10.04,8.013,21.015,19]tricosa-2,4(8),9,13,15(19),20-hexaen-23-yl)ethanone
15-acetyl-5,6,12,13-tetrahydrocycloocta[1,2-f:5,6-f']bis[1,3]benzodioxol-5,12-imine化学式
CAS
167491-69-2
化学式
C20H17NO5
mdl
——
分子量
351.359
InChiKey
HCMZTUUUKUXOFC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    26
  • 可旋转键数:
    0
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    57.2
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of new TNF-α Inhibitors and their biological properties
    作者:Norio Fujiwara、Yutaka Ueda、Naohito Ohashi
    DOI:10.1016/0960-894x(96)00103-5
    日期:1996.4
    New pavine alkaloid derivatives with various substitutions on their aromatic rings and nitrogen atom were prepared and evaluated for their inhibitory activity against TNF-alpha production in mouse macrophages stimulated with LPS. Some compounds showed potent inhibitory activities in vitro and protected mice against lethality of septic shock induced by LPS and D-galactosamine. Copyright (C) 1996 Elsevier Science Ltd
  • US5648359A
    申请人:——
    公开号:US5648359A
    公开(公告)日:1997-07-15
  • Tumor necrosis factor production inhibitors
    申请人:Sumitomo Pharmaceuticals Company, Limited
    公开号:US05648359A1
    公开(公告)日:1997-07-15
    There is provided a composition for inhibiting the production or secretion of tumor necrosis factor effective for the treatment of cachexia, septic shock, multiple organ failure, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, osteoarthritis, Behcet disease, systemic lupus erythematosus (SLE), graft versus host disease (GvHD), malaria, acquired immune deficiency syndrome (AIDS), meningitis, hepatitis and Type II diabetes mellitus. The composition comprises a pharmaceutically effective amount of a compound of formula (1).
    提供了一种用于抑制肿瘤坏死因子的产生或分泌的组合物,用于治疗消瘦症、脓毒性休克、多器官功能衰竭、类风湿性关节炎、炎症性肠病、多发性硬化、骨关节炎、贝赫切病、系统性红斑狼疮(SLE)、移植物抗宿主病(GvHD)、疟疾、获得性免疫缺陷综合症(AIDS)、脑膜炎、肝炎和2型糖尿病的有效组合物。该组合物包括化合物(1)的药用有效量。
查看更多

同类化合物

罗通定 屈昔多巴杂质6 N-甲基厚壳桂碱 O-methylcaryachine 2-methoxy-5,6,11,12-tetrahydro-dibenzo[a,e]cyclooctene-5,11-imin-11-carbamide 13,13-dimethyl-5,6,11,12-tetrahydro-5,11-epimino-dibenzo[a,e]cyclooctenium; iodide 2,3,8,9-tetraacetoxy-13-acetyl-5,6,11,12-tetrahydrodibenzo[a,e]cycloocten-5,11-imine 13-[3-(4-fluorophenyl)propyl]-5,6,11,12-tetrahydrodibenzo[a,e]cycloocten-5,11-imine-2,3,8,9-tetrol hydrochloride 13-ethyl-5,6,11,12-tetrahydrodibenzo[a,e]cycloocten-5,11-imine-2,3,8,9-tetrol hydrochloride (+)-caryachine Crychine (+/-)-N-norbisnorargemonine pavine (1S)-5,12-dimethoxy-17-methyl-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene-4,13-diol (1S,12S)-16-methoxy-20-methyl-5,7-dioxa-20-azapentacyclo[10.7.1.02,10.04,8.013,18]icosa-2,4(8),9,13,15,17-hexaen-15-ol escholtzine (-)-bisnorargemonine Argemonine (-)-argemonine (+/-)-N-ethoxycarbonylpavine 1-[(1S,9R)-4,5,12,13-tetramethoxy-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaen-17-yl]ethanone (1S,9R)-4,5,12,13-tetramethoxy-17-methyl-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene (1R,9S)-4,5,12,13-tetramethoxy-17-methyl-17-azoniatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene (1S,9S)-4,5,12,13-tetramethoxy-17-methyl-17-azoniatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene (1S,9S)-4,13-dimethoxy-17-methyl-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2(7),3,5,10,12,14-hexaene-3,12-diol 1-[(1S,9S)-4,5,12,13-tetramethoxy-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaen-17-yl]ethanone (1R,9S)-4,5,12,13-tetramethoxy-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene Californine-M, (demethylene-) 2AC Californine-M, (demethylene-methyl-) isomer-2 AC 4,5,12,13-Tetramethoxy-17,17-dimethyl-17-azoniatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene 13-methyl-5,6,11,12-tetrahydro-5,11-epimino-dibenzo[a,e]cyclooctene Dibenzo[a,e]cycloocten-5,11-imin-4-ol, 5,6,11,12-tetrahydro-3,8-dimethoxy-13-methyl- Californine-M, (di-(demethylene-methyl-)), isomer-3, 2AC Californine-M, (di-(demethylene-methyl-)), isomer-2, 2AC Californine-M (nor-demethylene) 3AC Californine-M, (di-(demethylene-methyl-)), isomer-1, 2AC (1R,9R)-4,5,12,13-tetramethoxy-17-methyl-17-azoniatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene (+)-Argemonine 17,17-Dimethyl-17-azoniatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene (±)-pavine 2-Methoxy-5,6,11,12-tetrahydro-dibenzocycloocten-5,11-imin 4,5,12,13-Tetramethoxy-17-prop-2-enyl-17-azatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene;hydrochloride Dibenzo[a,e]cycloocten-5,11-imine, 5,6,11,12-tetrahydro-2,3,8,9-tetramethoxy-13-(2-propenyl)- Benzo(5,6)cycloocta(1,2-f)-1,3-benzodioxol-5,11-imine, 5,6,11,12-tetrahydro-8,9-dimethoxy-14-methyl-, (5S)- 15-acetyl-5,6,12,13-tetrahydrocycloocta[1,2-f:5,6-f']bis[1,3]benzodioxol-5,12-imine 14-acetyl-5,6,11,12-tetrahydrobenzo[5,6]cycloocta[1,2-f]-1,3-benzodioxol-5,11-imine-8,9-diol 13-acetyl-5,6,11,12-tetrahydrodibenzo[a,e]cycloocten-5,11-imine-2,3,8,9-tetrol norargemonine 4,5,12,13-Tetramethoxy-17-methyl-17-oxido-17-azoniatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene (±)-pavine